• 1
    Walker JJ. Pre-eclampsia. Lancet 2000; 356: 12601265.
  • 2
    Confidential enquires. The National Institute for Clinical Excellence, Scottish Executive Health Department; Department of Heath, Social Services and Public Safety, Northern Ireland: The fifth report of the confidential enquires into maternal deaths in the United Kingdom 1997–1999. RCOG Press: London, 2001; 7691.
  • 3
    Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001; 357: 5356.
  • 4
    Khong TY, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small for gestational age infants. Br J Obstet Gynaecol 1986; 93: 10491059.
  • 5
    Pinenborg R, Anthony J, Davey DA, Rees A, Tiltman A, Vercruysse L, van Assche A. Placental bed spiral arteries in the hypertensive disorders of pregnancy. Br J Obstet Gynaecol 1991; 98: 648655.
  • 6
    Shanklin DR, Sibai BM. Ultrastructural aspects of pre-eclampsia. I: Placental bed and boundary vessels. Am J Obstet Gynecol 1989; 161: 735741.
  • 7
    Raty R, Koskinen P, Alanen A, Irjala K, Matinlauri I, Ekblad U. Prediction of pre-eclampsia with maternal mid-trimester total renin, inhibin A, AFP and free β-hCG levels. Prenat Diagn 1999; 19: 122127.
  • 8
    Yaron Y, Cherry M, Kramer RL. Second trimester maternal serum screening: maternal serum α-fetoprotein, β-chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999; 181: 968974.
  • 9
    Pouta AM, Hartikained AL, Vuolteenaho OJ, Ruokonen AO, Laatikainen TJ. Mid trimester N-terminal proatrial natriuretic peptide, free beta hCG and alpha fetoprotein in predicting pre-eclampsia. Obstet Gynecol 1998; 91: 940944.
  • 10
    Aquilina J, Maplethorpe R, Ellis P, Harrington K. Correlation between second trimester maternal serum inhibin-A and human chorionic gonadotrophin for the prediction of pre-eclampsia. Placenta 2000; 21: 487492.
  • 11
    Lambert-Messerlian GM, Silver HM, Petraglia F, Luisi S, Pezzani I, Maybruck WM, Hogge WA, Hanley-Yanez K, Roberts JM, Neveux LM, Canick JA. Second trimester levels of maternal serum human chorionic gonadotropin and inhibin A as predictors of pre-eclampsia in the third trimester of pregnancy. J Soc Gynecol Investig 2000; 7: 170174.
  • 12
    Cuckle H, Sehmi I, Jones R. Maternal serum inhibin A can predict pre-eclampsia. Br J Obstet Gynaecol 1998; 105: 11011103.
  • 13
    Aquilina J, Barnett A, Thompson O, Harrington K. Second trimester maternal serum inhibin concentrations as an early marker for pre-eclampsia. Am J Obstet Gynecol 1999; 181: 131136.
  • 14
    Ong CYT, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free beta human chorionic gonadotropin and pregnancy associated plasma protein-A as predictors of pregnancy complications. BJOG 2000; 107: 12651270.
  • 15
    Sebire NJ, Roberts L, Noble P, Wallace E, Nicolaides KH. Raised maternal serum inhibin A concentration at 10 to 14 weeks of gestation is associated with pre-eclampsia. BJOG 2000; 107: 795797.
  • 16
    Spencer K, Yu CKH, Cowans NJ, Otigbah C, Nicolaides KH. Prediction of pregnancy complications by first trimester maternal serum PAPP-A and free β-hCG and with second trimester uterine artery Doppler. Prenat Diagn 2005; 25: 949953.
  • 17
    Muttukrishna S, North RA, Morris J, Schellenberg JC, Taylor RS, Asselin J, Ledger W, Groome N, Redman CW. Serum inhibin A and activin A are elevated prior to the onset of pre-eclampsia. Hum Reprod 2000; 15: 16401645;Erratum in Hum Reprod 2001; 16: 2477.
  • 18
    Ong CYT, Liao AW, Munim S, Spencer K, Nicolaides KH. First trimester maternal serum activin A in pre-eclampsia and fetal growth restriction. J Matern Fetal Neonatal Med 2004; 15: 176180.
  • 19
    Yu CKH, Lakasing L, Papageorghiou AT, Spencer K, Nicolaides KH. Uterine artery Doppler and mid trimester maternal plasma homocysteine in subsequent pre-eclampsia. J Matern Fetal Neonatal Med 2004; 16: 134139.
  • 20
    Sorensen TK, Malinow MR, Williams MA, King IB, Luthy DA. Elevated second trimester serum homocysteine levels and subsequent risk of pre-eclampsia. Gynecol Obstet Invest 1999; 48: 98103.
  • 21
    Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, Morgan JP, Sellke FW, Stillman IE, Epstein FH, Sukhatme VP, Karumanchi SA. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension and proteinuria in pre-eclampsia. J Clin Invest 2003; 111: 649658.
  • 22
    Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi SA. Circulating angiogenic factors and the risk of pre-eclampsia. N Engl J Med 2004; 350: 672683.
  • 23
    Polliotti BM, Fry AG, Saller DN, Mooney RA, Cox C, Miller RK. Second trimester maternal serum placental growth factor and vascular endothelial growth factor for predicting severe, early onset pre-eclampsia. Obstet Gynecol 2003; 101: 12661274.
  • 24
    Taylor RN, Grimwood J, Taylor RS, McMasters MT, Fisher SJ, North RA. Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathological pregnancies. Am J Obstet Gynecol 2003; 188: 177182.
  • 25
    Wolf M, Sandler L, Munoz K, Hsu K, Ecker JL, Thadhani R. First trimester insulin resistance and subsequent pre-eclampsia: a prospective study. J Clin Endocrinol Metab 2002; 87: 15631568.
  • 26
    Yu CKH, Papageorghiou AT, Bindra R, Spencer K, Nicolaides KH. Second trimester sex hormone binding globulin and subsequent development of pre-eclampsia. J Matern Fetal Neonatal Med 2004; 16: 158162.
  • 27
    Spencer K, Yu CKH, Rembouskos G, Bindra R, Nicolaides KH. First trimester sex hormone binding globulin and subsequent development of pre-eclampsia or other adverse pregnancy complications. Hypertens Pregnancy 2005; 24: 303311.
  • 28
    Wald NJ, Morris JK. Multiple marker second trimester screening for pre-eclampsia. J Med Screen 2001; 8: 6568.
  • 29
    Wald NJ, Morris JK, Ibison J, Wu T, George LM. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers. Prenat Diagn 2006; 26: 559564.
  • 30
    Aquilina J, Thompson O, Thilaganathan B, Harrington K. Improved early prediction of pre-eclampsia by combining second-trimester maternal serum inhibin A and uterine artery Doppler. Ultrasound Obstet Gynecol 2001; 17: 477484.
  • 31
    Spencer K, Yu CKH, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy associated plasma protein-A, free β-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks' gestation. Ultrasound Obstet Gynecol 2006; 27: 658663.
  • 32
    Papageorghiou AT, Yu CKH, Bindra R, Pandis G, Nicolaides KH. Mutlicenter screening for pre-eclampsia and fetal growth restriction by transvaginal uterine artery Doppler at 23 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 441449.
  • 33
    Papageorghiou AT, Yu CK, Cicero S, Bower S, Nicolaides KH. Second trimester uterine artery Doppler screening in unselected populations: a review. J Matern Fetal Neonatal Med 2002; 12: 7888.
  • 34
    Martin AM, Bindra R, Curcio P, Cicero S, Nicolaides KH. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11–14 weeks of gestation. Ultrasound Obstet Gynecol 2001; 18: 583586.
  • 35
    Gomez O, Martinez JM, Figueras F, Del Rio M, Borobio V, Puerto B, Coll O, Cararach V, Vanrell JA. Uterine artery Doppler at 11–14 weeks of gestation to screen for hypertensive disorders and associated complications in an unselected population. Ultrasound Obstet Gynecol 2005; 26: 490494.
  • 36
    Burger O, Pick E, Zwickel J, Klayman M, Meiri H, Slotky R, Mandel S, Rabinovitch L, Paltieli Y, Admon A, Gonen R. Placental protein 13 (PP-13): Effects on cultured trophoblasts, and its detection in human body fluids in normal and pathological pregnancies. Placenta 2004; 25: 608622.
  • 37
    Than NG, Pick E, Bellyei S, Szigeti A, Burger O, Berente Z, Janaky T, Boronkai A, Kliman H, Meir H, Bohn H, Than GN, Sumegi B. Functional analysis of placenta protein 13/galectin 13. Eur J Biochem 2004; 271: 10651078.
  • 38
    Visegrady B, Than NG, Kiler F, Sumegi B, Than GN, Bohn H. Homology modelling and molecular dynamic studies of human placental tissue protein 13 (galectin-13). Protein Eng 2004; 14: 875880.
  • 39
    Tarsa M, Hull AD, Moore TR, Bogic LV. Gene expression profiles suggest pre-inflammatory predominance at the maternal–fetal interface in severe pre-eclapmsia at preterm (sPPE). In Signaling and the Placental; Proceeding of the Placenta Association of the American Conference, September 25–29, Asilomar, CA, Insley J, Myatt L (eds).
  • 40
    Nicolaides KH, Bindra R, Turzan OM, Chefetz I, Sammar M, Meiri H, Tal J, Cuckle HS. A novel approach to first trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet Gynecol 2006; 27: 1317.
  • 41
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free ß-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231237.
  • 42
    Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one stop clinic. A review of three years prospective experience. BJOG 2003; 110: 281286.
  • 43
    Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892898.
  • 44
    Spencer K, Ong CY, Liao AW, Nicolaides KH. The influence of ethnic origin on first trimester biochemical markers of chromosomal abnormalities. Prenat Diagn 2000; 20: 491494.
  • 45
    Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free beta-hCG MoM when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003; 23: 851855.
  • 46
    Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 2004; 24: 169173.
  • 47
    Spencer K, Heath V, El-Sheikhah A, Ong CYT, Nicolaides KH. Ethnicity and the need for correction of biochemical and ultrasound markers of chromosomal anomalies in the first trimester: a study of Oriental, Asian and Afro-Caribbean populations. Prenat Diagn 2005; 25: 365369.